On September 6, 2022 Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Master Key therapies, reported that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the H.C. Wainwright 24th Annual Global Investment Conference (Press release, Black Diamond Therapeutics, SEP 6, 2022, View Source [SID1234619071]). The presentation will be available for on-demand viewing beginning Monday, September 12, 2022, starting at 7:00 AM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Black Diamond Therapeutics management will also participate in investor meetings at the Morgan Stanley 20th Annual Global Healthcare Conference being held from Monday, September 12th to Wednesday, September 14th, 2022, in New York, NY.

A webcast of the H.C. Wainwright presentation can be accessed by visiting the investors relations section of the Company’s website at: www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived on for 90 days following the event.